Our Science - Kodiak Sciences

ABCD PLATFORM

Our Antibody Biopolymer Conjugate Drug (ABCD) Platform is at the heart of our portfolio of next generation retinal medicines

1 Molecule, 1 Target

1 Molecule, 2 Targets

1 Molecule, Many targets

A PRODUCT PLATFORM ENABLING MULTI-MECHANISM THERAPIES EMPOWERED FOR DURABILITY

The ABCD Platform is purposefully designed for durability and powered to combine multiple modalities, such as proteins and bioactive molecules at a high drug-to-antibody ratio, in a single therapeutic

Explore the unique components of the ABCD Platform:

Engineered to exhibit high binding affinity and specificity. It can be any protein therapeutic, such as a monospecific or bispecific antibody.

Conjugated to the biopolymer via a stable, site-specific linkage.

A bioinspired polymer that is engineered to make medicines last longer and extend their therapeutic benefit. It is also powered to combine multiple modalities.

The biopolymer is optically clear and made of phosphorylcholine, the primary hydrophilic component of human cell membranes. It creates a water force field around the protein therapeutic without obstructing the binding sites, shielding it from non-specific interactions and providing greater on-target potency.

Small molecules and other bioactive molecules at a high drug-to-antibody (DAR) ratio can be embedded and released over time to enable treatment of complex, multifactorial diseases.

Enables the use of mechanistic bioactive molecules versus today’s Antibody Drug Conjugates (ADCs) whose low DAR limits use to cytotoxic agents.

A single therapeutic purposefully designed for durability and powered to combine multiple modalities for complex ocular and systemic diseases.

More than the sum of its parts

A single therapeutic purposefully designed for durability and powered to combine multiple modalities for complex ocular and systemic diseases.

Ursus, Kodiak’s custom commercial scale manufacturing facility designed for complex antibody conjugate biotherapies, is successfully commissioned as a cGMP facility for Kodiak’s ABC medicines.

SEE THE ABCD PLATFORM IN ACTION

The ABCD Platform is inspired by nature and designed with water in mind. Travel through the eye to see how ABCD medicines are engineered for increased durability and efficacy

The ABC Platform uses a bio-inspired polymer to orchestrate water around the antibody without obstructing the binding sites, preventing non-specific interactions

The ABC molecule can slip through crowded or tight areas like retina tissue, that would otherwise impede it

The high lubricity of the ABC molecule allows it to have ultra low friction, enabling it to penetrate tissues

Water influences antibody potency, enabling the ABC molecule to bind to its target with high affinity and specificity

Follow the water: launch the ABCD digital experience →

MORE THAN THE SUM OF ITS PARTS

The ABCD Platform structures water at critical binding interfaces to make medicines last longer in the eye and improve their therapeutic benefit

Extended Intraocular Half-life

Medicines built on the ABCD Platform (e.g., tarcocimab tedromer) last longer and better maintain therapeutic concentration levels in the eye

Excellent Retinal Bioavailability

The ABCD Platform improves therapeutic absorption and distribution in the eye

Deeper Inhibitory Potency

The ABCD Platform shields the antibody from non-specific binding thereby providing greater on-target potency

Fast Systemic Clearing

Medicines built on the ABCD Platform are designed to clear the body quickly after exiting the eye

PUSHING THE BOUNDARIES

ABCD PLATFORM

A PRODUCT PLATFORM ENABLING MULTI-MECHANISM THERAPIES EMPOWERED FOR DURABILITY

SEE THE ABCD PLATFORM IN ACTION

MORE THAN THE SUM OF ITS PARTS

TAKE A 3-DIMENSIONAL TOUR